Bernhard Suter

Dr. Bernhard Suter


Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 April 2015 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
JNJeffrey Lorenz Neul
Jeffrey Lorenz Neul
DGDaniel G. Glaze
Daniel G. Glaze
APAlan K Percy
Alan K Percy
TFTim J Feyma
Tim J Feyma
ABArthur Allen Beisang
Arthur Allen Beisang
NJNancy E. Jones
Nancy E. Jones
Rett syndrome is a genetically based neurodevelopmental disorder. Although the clinical consequences of Rett syndrome are profound and lifelong, currently no approved drug treatments are available specifically targeted to Rett symptoms. High quality outcome measures, specific to the core symptoms of a disorder are a critical component of well-designed clinical trials for individuals with neurodevelopmental disorders. The Clinical Global Impression Scale is a measure of global clinical change with strong face validity that has been widely used as an outcome measure in clinical trials of central nervous system disorders. Despite its favorable assay sensitivity in clinical trials, as a global measure, the Clinical Global Impression Scale is not specific to the signs and symptoms of the disorder under study. Development of key anchors for the scale, specific to the disorder being assessed, holds promise for enhancing the validity and reliability of the measure for disorders such as Rett syndrome.

15 September 2024 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
SBSameer S Bajikar
Sameer S Bajikar
YSYehezkel Sztainberg
Yehezkel Sztainberg
ASAlexander Jonathan Shao
Alexander Jonathan Shao
HTHarini P Tirumala
Harini P Tirumala
YWYing-Wooi Wan
Ying-Wooi Wan
HZHuda Y Zoghbi
Huda Y Zoghbi
Genomic copy-number variations (CNVs) that can cause neurodevelopmental disorders often encompass many genes, which complicates our understanding of how individual genes within a CNV contribute to pathology. MECP2 duplication syndrome (MDS or MRXSL in OMIM; OMIM#300260) is one such CNV disorder caused by duplications spanning methyl CpG-binding protein 2 (MECP2) and other genes on Xq28. Using an antisense oligonucleotide (ASO) to normalize MECP2 dosage is sufficient to rescue abnormal neurological phenotypes in mouse models overexpressing MECP2 alone, implicating the importance of increased MECP2 dosage within CNVs of Xq28. However, because MDS CNVs span MECP2 and additional genes, we generated human neurons from multiple MDS patient-derived induced pluripotent cells (iPSCs) to evaluate the benefit of using an ASO against MECP2 in a MDS human neuronal context. Importantly, we identified a signature of genes that is partially and qualitatively modulated upon ASO treatment, pinpointed genes sensitive to MeCP2 function, and altered in a model of Rett syndrome, a neurological disorder caused by loss of MeCP2 function. Furthermore, the signature contained genes that are aberrantly altered in unaffected control human neurons upon MeCP2 depletion, revealing gene expression programs qualitatively sensitive to MeCP2 levels in human neurons. Lastly, ASO treatment led to a partial rescue of abnormal neuronal morphology in MDS neurons. All together, these data demonstrate that ASOs targeting MECP2 benefit human MDS neurons. Moreover, our study establishes a paradigm by which to evaluate the contribution of individual genes within a CNV to pathogenesis and to assess their potential as a therapeutic target.

9 November 2020 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
SPSarika U. Peters
Sarika U. Peters
CFCary Fu
Cary Fu
EMEric D. Marsh
Eric D. Marsh
TBTim A. Benke
Tim A. Benke
BSBernhard Suter
Bernhard Suter
JNJeffrey L. Neul
Jeffrey L. Neul

19 May 2018 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
MZManar Zaghlula
Manar Zaghlula
DGDaniel G. Glaze
Daniel G. Glaze
GEGregory M. Enns
Gregory M. Enns
LPLorraine Potocki
Lorraine Potocki
ASAloysia L. Schwabe
Aloysia L. Schwabe
BSBernhard Suter
Bernhard Suter

21 December 2024 in Trials
Verified
Journal Article
Open access
PDF file
JDJenny Downs
Jenny Downs
DPDominique C. Pichard
Dominique C. Pichard
WKWalter E. Kaufmann
Walter E. Kaufmann
JHJoseph P. Horrigan
Joseph P. Horrigan
MRMelissa Raspa
Melissa Raspa
TBTim Benke
Tim Benke
Introduction: The clinical, research and advocacy communities for Rett syndrome are striving to achieve clinical trial readiness, including having fit-for-purpose clinical outcome assessments. This study aimed to (1) describe psychometric properties of clinical outcome assessment for Rett syndrome and (2) identify what is needed to ensure that fit-for-purpose clinical outcome assessments are available for clinical trials. Methods: Clinical outcome assessments for the top 10 priority domains identified in the Voice of the Patient Report for Rett syndrome were compiled and available psychometric data were extracted. The clinical outcome assessments measured clinical severity, functional abilities, comorbidities and quality of life, and electrophysiological biomarkers. An international and multidisciplinary panel of 29 experts with clinical, research, psychometric, biostatistical, industry and lived experience was identified through International Rett Syndrome Foundation networks, to discuss validation of the clinical outcome assessments, gaps and next steps, during a workshop and in a follow-up questionnaire. The identified gaps and limitations were coded using inductive content analysis. Results: Variable validation profiles across 26 clinical outcome assessments of clinical severity, functional abilities, and comorbidities were discussed. Reliability, validity, and responsiveness profiles were mostly incomplete; there were limited content validation data, particularly parent-informed relevance, comprehensiveness and comprehensibility of items; and no data on meaningful change or cross-cultural validity. The panel identified needs for standardised administration protocols and systematic validation programmes. Conclusion: A pipeline of collaborative clinical outcome assessment development and validation research in Rett syndrome can now be designed, aiming to have fit-for-purpose measures that can evaluate meaningful change, to serve future clinical trials and clinical practice.

21 January 2025 in Annals of Clinical and Translational Neurology
Verified
Journal Article
Open access
DPDavut Pehlivan
Davut Pehlivan
CHChengjun Huang
Chengjun Huang
HHHolly K. Harris
Holly K. Harris
CCChristine Coquery
Christine Coquery
AMAditya Mahat
Aditya Mahat
BSBernhard Suter
Bernhard Suter
Objective: Rett syndrome (RTT) and MECP2 duplication syndrome (MDS) result from under‐ and overexpression of MECP2, respectively. Preclinical studies using genetic‐based treatment showed robust phenotype recovery for both MDS and RTT. However, there is a risk of converting MDS to RTT, or vice versa, if accurate MeCP2 levels are not achieved. The aim of this study was to identify biomarkers distinguishing RTT from MDS.Materials and Methods: We prospectively enrolled 11 MDS and 6 male RTT like (MRL) individuals for a panel of clinical and neurophysiological assessments over two visits, 8–10 months apart.Results: We identified numerous clinical and physiological features as promising biomarkers. MRL individuals exhibited large amplitude whole body tremor, midline stereotypies (vs. hand flapping at sides in MDS), earlier neuromotor regression, and earlier onset but less commonly refractory epilepsy. In the neurophysiological domain, we observed several marked differences in sleep physiology between MDS/MRL and typically developing (TD) individuals including reduced sleeping time, increased delta power during rapid eye movement (REM) sleep, decreased occipital alpha and increased brain‐wide delta power during wakefulness, and reduced spindle density and duration. MRL individuals also had much lower delta power during NREM 2 and 3 stages than the TD group. We found differences in spindle duration in the temporal lobes and spindle amplitude in the frontal lobes between MDS and MRL.Discussion: Our study revealed distinct clinical features of MDS and MRL that can be monitored during a clinical trial and may serve as target engagement, disease progression, or safety biomarkers for interventional studies.